Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class, ...

Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...

Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4'24 concurrent with significantly lower operating expenses - - Company reports positive quarterly ...

The Chinese health care technology sector is in the midst of a transformative phase, fueled by breakthroughs in artificial intelligence drug discovery and power ...

A September 2024 article in the journal Biomedicines reviewing the findings of clinical trials for ivermectin and chloroquine ...

Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the ...

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence ...

Find out what led biotech to a situation where women are underrepresented in clinical trials and how the industry is ...

In a research article published in JAMA Surgery, Brian Fry, M.D., M.S., a general surgery resident at University of Michigan Health and colleagues compared hernia recurrence rates after undergoing ...

Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and ...

NanoViricides, Inc. (the “Company”)(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape, declared today that its ...